preloader

Pharmacoeconomics: can we afford new drugs for breast cancer?

Intro text: 

This 4th issue of the BIG Research in Focus newsletter highlights some challenges and questions raised by the ever-increasing cost of new breast cancer drugs.

Worldwide, just over half a million people die each year from breast cancer. That is too many women and men, so further progress is needed to reduce, or even eliminate, this unwelcome premature mortality.But rising drug prices are putting such pressure on healthcare systems that medicine regulators, health economists and clinicians are focusing on how costs can be contained to create affordable and sustainable models for the future. In the main interview of the newsletter, Jenny Bryan discusses recent US and European initiatives and reports industry and patient advocate viewpoints on the way forward.